AlphAIAlphAI — Financial news for AI agents
investing.comNOV 32 min read$AXSM

B.Riley reiterates Buy on Axsome stock, keeps $300 target

B.Riley reiterated a Buy rating and $300 target on Axsome Therapeutics (AXSM) after its Q3 2026 results. Revenue was $259.7M, up 52% YoY, beating estimates. AUVELITY revenue reached $207.6M, up 53% YoY. B.Riley expects cash flow breakeven in Q4 2026. AXSM stock fell premarket despite strong results.

Original reporting
investing.com
Published Nov 3, 2026, 9:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AXSM
Bearish
high confidence
Mentioned
$AXSM
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AXSMBearishMed
01

Why it matters

The earnings beat provides fresh data for valuation models, but the stock's pre‑market decline suggests market concern over spending and future growth.

02

Market read

First‑report earnings release for a micro‑cap biotech; relevant for traders focused on biotech earnings and cash‑flow outlooks.

03

What to watch

Cash balance of $314M may extend runway, and upcoming Phase 3 readouts in 2027 could be catalysts.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Axsome Therapeutics announced its Q3 2026 earnings, highlighting strong revenue growth and a narrower loss, while noting cash‑flow breakeven expectations in Q4.

Company-level read

Ticker impact

$AXSMBearishHigh confidence
Context

Axsome Therapeutics reported Q3 2026 results with revenue $259.7M up 52% YoY, beating estimates, and a narrower adjusted loss of $0.25 per share.

Expected impact

likely pressure as the market prices in spending concerns despite the revenue beat

Evidence & confidence

The earnings surprise is fresh and material, but investor sentiment is cautious given high cash outflows.

Market effects

Sector

Biotech sector may see modest pullback as investors reassess cash‑flow timelines for similar companies.

Regional

US biotech stocks could see slight downside pressure in early trading.

Global

Limited to US‑listed biotech; no broader market effect expected.

Counterpoint

What could challenge this read

The revenue beat and strong gross margin could support a short‑term bounce if buying pressure returns.

Key entities

  • company
    Axsome Therapeutics

    US‑listed biotech firm (NASDAQ:AXSM) reporting Q3 2026 results.

Read at source← All news

Related articles

NOV 3
$AXSMMed

Axsome Therapeutics Earnings Call Signals Broad Growth

Axsome Therapeutics (AXSM) reported Q3 revenue of $260M, up 52% YoY. AUVELITY sales rose 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company cited growth in prescriptions and prescribers, but noted concerns like higher expenses and limited SYMBRAVO coverage.

tipranks.com3 min
NOV 2
$AXSMMedAI 8/10

Axsome Therapeutics, Inc. Q3 2026 Earnings Call Summary

Axsome Therapeutics reported Q3 2026 revenue growth of 52% YoY, driven by AUVELITY's performance in MDD and ADA, with total revenue surpassing $1B annually. Net loss narrowed to $12.9M due to operating leverage. AUVELITY saw sequential growth, with primary care prescribers being a key driver. The company maintained a gross margin in the low to mid-90% range. Management expects continued growth and sufficient cash to reach cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMedAI 8/10

Axsome (AXSM) Q3 2026 Earnings Call Transcript

Axsome (AXSM) reported Q3 2026 revenue of $260M, up 52% YoY. AUVELITY sales grew 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company highlighted strong prescription growth for AUVELITY, particularly in Alzheimer's agitation and major depressive disorder indications, and expects continued momentum. SYMBRAVO sales also grew 88% YoY to $3.9M. The company maintains a strong cash position and anticipates cash flow positivity.

finance.yahoo.com2 min